What is SymKardia?
SymKardia, Inc. is a U.S.-based medical device company pioneering a novel approach to cardiac arrhythmia treatment through cardiac neuromodulation. Diverging from traditional therapies that directly impact heart tissue, SymKardia is developing technologies designed to modulate the nervous system pathways that govern heart function. This innovative strategy aims to achieve more precise and effective management of cardiac rhythms, positioning the company at the forefront of advanced cardiovascular care.
How much funding has SymKardia raised?
SymKardia has raised a total of $500K across 1 funding round:
Debt
$500K
Debt (2026): $500K, investors not publicly disclosed
What's next for SymKardia?
The recent major strategic investment signals a pivotal moment for SymKardia, likely enabling the company to accelerate its research and development initiatives, scale its operations, and advance its cardiac neuromodulation technology towards clinical trials and market entry. This capital infusion is expected to fuel further innovation and solidify its position in the competitive medical device landscape, particularly within the specialized field of cardiac rhythm management.
See full SymKardia company page
